Overview

Study of Different Doses of a Novel Treatment for Onychomycosis

Status:
Completed
Trial end date:
2007-07-31
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the safety and efficacy of 2.5%, 5.0%, and 7.5% AN2690 Solutions compared to the vehicle alone in the treatment of distal, subungual onychomycosis of the great target toenail.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Treatments:
Pharmaceutical Solutions
Tavaborole